Inner City Asthma consortium 3 (ICAC3)

内城哮喘协会 3 (ICAC3)

• 批准号: 9110805
• 负责人: William W. Busse
• 金额: $ 1032.87万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-05 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9110805
• 关键词: 16 year old; Address; Adolescence; Adolescent; Allergen Immunotherapy; Allergens; Allergic; Anti-Cholinergics; Asthma; Bacteria; Biological; Birth; Caring; Cells; Characteristics; Child; Childhood; Childhood Asthma; Clinical; Cohort Studies; Collaborations; Complex; Development; Dictyoptera; Disease; Disease Progression; Disease remission; Environment; Environmental Exposure; Environmental Risk Factor; Epidemic; Epigenetic Process; Epitopes; Exposure to; Goals; Grant; Guidelines; House Dust; Household; IgE; Immune; Immune response; Immunobiology; Immunologics; Immunotherapy; Incidence; Interleukin-5; Intervention; Lead; Leptin; Life; Link; Mediating; Metabolic; Microbe; Multicenter Studies; Muscarinic Antagonists; Obesity; Outcome; Participant; Peripheral Blood Eosinophilia; Phenotype; Plasma; Population; Prevalence; Prevention; Process; Protocols documentation; Recurrence; Research Design; Respiratory Tract Infections; Risk; Risk Factors; Role; School-Age Population; Severities; Shapes; Source; Stimulus; Systems Biology; T cell response; T-Lymphocyte; Testing; Wheezing; Work; airborne allergen; allergic airway disease; asthmatic; asthmatic patient; base; cockroach allergen; cohort; design; disorder control; early childhood; genetic risk factor; gut microbiome; high risk; immunoregulation; improved; in utero; infancy; inner city; mepolizumab; microbial; microbiome; mouse allergen; omalizumab; prevent; respiratory; response; subcutaneous; therapy design

DESCRIPTION (provided by applicant): ICAC's goal is to include further development of cockroach allergen immunotherapy and consideration of new allergen immunotherapies; for example to mouse allergens; the development and execution of clinical and mechanistic studies targeted to inner-city asthma phenotypes, and interventions designed to prevent the incidence of asthma or its progression. In addition, the URECA birth cohort study will be continued to the end of the grant, when the participants will range from 14 to 16 years of age, with the goal to provide information on the immunologic basis of late childhood and adolescence-onset asthma, as well as the remission of asthma during the same years.

简介(申请人提供)：廉政公署的目标是进一步发展蟑螂过敏原免疫疗法和考虑新的过敏原免疫疗法；例如针对老鼠过敏原；发展和进行针对市内哮喘表型的临床和机制研究，以及旨在预防哮喘发病或发展的干预措施。此外，URECA的出生队列研究将持续到赠款结束，届时参与者的年龄将从14岁到16岁不等，目的是提供有关儿童后期和青春期哮喘的免疫学基础以及同一年哮喘缓解情况的信息。